Cardiovascular disease is a leading cause of death globally. At present, there are many ways to diagnose this pathophysiology. The greatest disadvantages related to current biomarkers are their low specificity, low selectivity and low accuracy. A new method, extensively studied recently, is the expression of miRNAs, used as genetic biomarkers for the early diagnosis of cardiovascular diseases. This paper presents an update of miRNAs species expression that can serve as early diagnostic biomarkers and for the continuous monitoring of patients with cardiovascular disease.
BACKGROUND
Cardiovascular disease is one of the leading causes of death globally. An important reason for the increased rates of morbidity and mortality in these patients is the late diagnosis of complicated cases that progress to cardiovascular emergencies. [1] [2] [3] In acute cardiac settings, a number of methods are used currently for evaluation based on biochemical-humoral biomarkers, such as cardiac troponin (TNC), creatine kinase-myocardial band isoform (CK-MB) and brain natriuretic peptide (BNP). [4] [5] [6] [7] Unfortunately, these biomarkers show low selectivity and specificity, and can often display false positive results due to their association with multiple pathophysiologies. A potential future biomarker, intensively studied lately, is the genetic expression of miRNAs. Essential features that make it the ideal candidate for use as a biomarker are its high selectivity and specificity. Moreover, investigation methods for miRNAs are noninvasive and inexpensive. [8] [9] [10] In this update paper, genetic and epigenetic modifications of miRNAs in cardiovascular emergencies are pre-sented, together with several miRNAs that can serve as biomarkers for early diagnosis of cardiac pathologies in acute settings.
BIOGENESIS AND BIOCHEmICAL CHARACTERISTICS Of miRNAS
miRNA biosynthesis takes place in the cell nucleus. 
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PANELS Of miRNA ExPRESSION IN ACUTE mYOCARDIAL INfARCTION
One of the most common syndromes associated with CAD is acute myocardial infarction (AMI). In practice, the bestknown biomarker for AMI is cardiac troponin I (cTnI). A major disadvantage of cTnI is the false positives that can occur in patients with atrial fibrillation, chronic kidney disease or septic shock. Wang et al. (2013) , in a study on the changes of miRNA expression in patients with AMI, showed a significant increase for miRNA-133a. 30 
